News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a …
The FDA has approved Lantheus Holdings Inc.'s Tauklarify (florquinitau F 18 injection) for PET scans to diagnose Alzheimer's disease in adults with cognitive impairment. This radiodiagnostic agent helps identify tau neurofibrillary tangle pathology. Lantheus plans to support Alzheimer's therapeutic programs and is evaluating commercial …
The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on …
[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer’s disease through positron emission tomography (PET). Specifically, the approval allows the …
The U.S. FDA has approved Lantheus Holdings' radioactive agent, Tauklarify, for use in brain scans to assess Alzheimer's disease by making abnormal tau protein deposits visible. This approval was based on two studies involving over 500 participants. While the tau-imaging market is currently dominated …
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 1,696,751 shares in Dianthus Therapeutics Inc. (DNTH), representing 3.1% of the company's outstanding common stock. This figure includes 510,400 shares issuable upon the exercise of call options. The filing indicates shared …
Lantheus Holdings, Inc. BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and …
Lantheus has received FDA approval for TAUKLARIFY (florquinitau F 18 injection), a PET imaging agent used to detect tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. The approval is based on two blinded read studies demonstrating high diagnostic …
LightInTheBox Holding Co., Ltd. (NYSE:LITB) successfully completed a private placement, raising approximately $5.49 million in gross proceeds by issuing 21,397,409 ordinary shares. Chairman and CEO Jian He invested $1.09 million in the financing, increasing his beneficial ownership to about 24.1%. The company plans to …
Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. …
LightInTheBox Holding Co., Ltd. (LITB) announced the completion of a private placement, raising approximately $5.49 million to accelerate its AI-driven strategic transformation. Chairman and CEO Jian He invested $1.09 million, increasing his beneficial ownership to 24.1%. The company plans to use the proceeds to …
Wellington Management entities have disclosed a passive beneficial ownership stake of approximately 5.9% (3,229,882 shares) in Dianthus Therapeutics (DNTH) through a Schedule 13G filing. The shares are held by clients of various Wellington investment advisers, with Wellington reporting shared voting and dispositive power but …
LightInTheBox Holding Co., Ltd. (NYSE:LITB) successfully completed a private placement on August 10, raising approximately $5.49 million by issuing over 21 million ordinary shares. Chairman and CEO Jian He invested about $1.09 million, increasing his beneficial ownership to 24.1%. The proceeds will be used …
LightInTheBox (NYSE: LITB) has successfully completed a private placement, raising approximately $5.49 million to fuel its AI-driven transformation. CEO Jian He personally invested about $1.09 million, increasing his beneficial ownership to 24.1%. The funds will be allocated to AI initiatives across product discovery, personalization, …
[Exterior Northrop Grumman office business building in Georgia modern glass facade with sign in capital city] krblokhin/iStock Editorial via Getty Images Northrop Grumman (NYSE) and Aeronix are jointly investing several million dollars to develop space-based cryptographic systems aimed at making classified communications faster and …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Northrop Grumman stock has returned 69.3% over the past 5 years, yet current checks suggest the shares may still trade below an estimate of intrinsic …
Simon Read, a director at Dianthus Therapeutics Inc. (NASDAQ:DNTH), sold approximately $304,231 worth of common stock on August 10, 2026. This transaction involved the exercise of stock options and subsequent sale of 2,777 shares, executed under a Rule 10b5-1 trading plan. Following these sales, …
Adam M. Veness, SVP of Dianthus Therapeutics (NASDAQ:DNTH), sold over $2.2 million worth of company common stock and acquired $357,599 through option exercises. These transactions occurred on August 7 and 10, 2026, under a pre-established trading plan, as the stock trades near its 52-week …
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $108.11. The company recently exceeded earnings and revenue expectations, reporting $1.55 EPS and $388.18 million in revenue. Institutional investors hold a significant 99.06% of the …
Earlier this month, Northrop Grumman announced two multi-year framework agreements totaling over US$3.00 billion to accelerate production of PAC-3 MSE solid rocket motors and THAAD components, alongside unveiling its new Raid Hunter 50mm gun-based air defense system for countering cruise missiles and drone swarms. …
An insider at Dianthus Therapeutics (DNTH) has sold shares valued at $844,822, as disclosed in a recent SEC filing. This transaction, reported on August 11, 2026, follows another recent insider sale of $2,208,833. Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Why the new missile defense agreements matter for Northrop Grumman stock Northrop Grumman (NOC) has signed two multi year framework agreements worth over …
Search by ticker symbol or company name and select a result to open its chart.